

Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Research Report 2026(Status and Outlook)

<https://marketpublishers.com/r/G18843671D69EN.html>

Date: February 2026

Pages: 205

Price: US\$ 2,980.00 (Single User License)

ID: G18843671D69EN

Abstracts

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on First in Class (FIC) Antibody Drug Conjugate (ADC) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations. A First-in-Class Antibody-Drug Conjugate (FIC ADC) is an innovative targeted cancer therapy that combines a monoclonal antibody, a cytotoxic payload, and a linker, and is the first approved therapeutic to act on a novel target or molecular mechanism in its class. These ADCs represent the first therapeutic option to deliver a toxic agent specifically to a previously untargeted cell surface antigen or use a unique payload mechanism.

The global First in Class (FIC) Antibody Drug Conjugate (ADC) market size was estimated at USD 2315.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.30% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the First in Class (FIC) Antibody Drug Conjugate (ADC) market.

Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Pfizer
Johnson & Johnson
AstraZeneca
Arvinas
GSK
Bayer Corporation
Pumis Biotechnology (BioNTech)
Telix
Merus
Bicara Therapeutics

Immatics
Fabhalta
Lytgobi
Talvey
Regeneron Pharmaceuticals
Ogsiveo
Skyclary
Truqap
Litfulo
Vertex Pharmaceuticals
Jiangsu Hengrui Medicine
Akeso, Inc
Dizal Pharma
Shenzhen Yipusheng
Foreseen Biotechnology
Shanghai Henlius Biotech, Inc.
Suzhou Yilian Biopharmaceutical
Beijing Hotgen Biotech
Lixin Pharmaceutical Technology
Suzhou Zejing Biopharmaceutical

Market Segmentation (by Type)

Large Molecule FIC Drugs
Small Molecule FIC Drugs

Market Segmentation (by Application)

Tumors and Cancers
Others

Geographic Segmentation

North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market
Overview of the regional outlook of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of First in Class (FIC) Antibody Drug Conjugate (ADC), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of First in Class (FIC) Antibody Drug Conjugate (ADC)

1.2 Key Market Segments

1.2.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type

1.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) Estimates and Forecasts (2020-2035)

2.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Estimates and Forecasts (2020-2035)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Product Life Cycle

3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Manufacturers (2020-2025)

3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Manufacturers (2020-2025)

3.5 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price by

Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Competitive Situation and Trends

3.8.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Concentration Rate

3.8.2 Global 5 and 10 Largest First in Class (FIC) Antibody Drug Conjugate (ADC)

Players Market Share by Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) INDUSTRY CHAIN ANALYSIS

4.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Industry News

5.4.1 New Product Developments

5.4.2 Mergers & Acquisitions

5.4.3 Expansions

5.4.4 Collaboration/Supply Contracts

5.5 PEST Analysis

5.5.1 Industry Policies Analysis

5.5.2 Economic Environment Analysis

5.5.3 Social Environment Analysis

5.5.4 Technological Environment Analysis

5.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Porter's Five Forces Analysis

5.6.1 Global Trade Frictions

5.6.2 U.S. Tariff Policy ? April 2025

5.6.3 Global Trade Frictions and Their Impacts to First in Class (FIC) Antibody Drug Conjugate (ADC) Market

5.7 ESG Ratings of Leading Companies

6 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2020-2025)

6.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (2020-2025)

6.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2020-2025)

7 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Sales by Application (2020-2025)

7.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) by Application (2020-2025)

7.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)

8 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SALES BY REGION

8.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region

8.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region

8.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region

8.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region

8.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region

8.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region

8.3 North America

8.3.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country

- 8.3.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
 - 8.3.3 U.S. Market Overview
 - 8.3.4 Canada Market Overview
 - 8.3.5 Mexico Market Overview
- 8.4 Europe
 - 8.4.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
 - 8.4.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
 - 8.4.3 Germany Market Overview
 - 8.4.4 France Market Overview
 - 8.4.5 U.K. Market Overview
 - 8.4.6 Italy Market Overview
 - 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
 - 8.5.1 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
 - 8.5.2 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
 - 8.5.3 China Market Overview
 - 8.5.4 Japan Market Overview
 - 8.5.5 South Korea Market Overview
 - 8.5.6 India Market Overview
 - 8.5.7 Southeast Asia Market Overview
- 8.6 South America
 - 8.6.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
 - 8.6.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
 - 8.6.3 Brazil Market Overview
 - 8.6.4 Argentina Market Overview
 - 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
 - 8.7.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
 - 8.7.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
 - 8.7.3 Saudi Arabia Market Overview
 - 8.7.4 UAE Market Overview
 - 8.7.5 Egypt Market Overview

8.7.6 Nigeria Market Overview

8.7.7 South Africa Market Overview

9 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET PRODUCTION BY REGION

9.1 Global Production of First in Class (FIC) Antibody Drug Conjugate (ADC) by Region(2020-2025)

9.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2020-2025)

9.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)

9.4 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production

9.4.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)

9.4.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)

9.5 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production

9.5.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)

9.5.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)

9.6 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (2020-2025)

9.6.1 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)

9.6.2 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)

9.7 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (2020-2025)

9.7.1 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)

9.7.2 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Pfizer

10.1.1 Pfizer Basic Information

10.1.2 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

10.1.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

10.1.4 Pfizer Business Overview

10.1.5 Pfizer SWOT Analysis

10.1.6 Pfizer Recent Developments

10.2 Johnson and Johnson

10.2.1 Johnson and Johnson Basic Information

10.2.2 Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Overview

10.2.3 Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Market Performance

10.2.4 Johnson and Johnson Business Overview

10.2.5 Johnson and Johnson SWOT Analysis

10.2.6 Johnson and Johnson Recent Developments

10.3 AstraZeneca

10.3.1 AstraZeneca Basic Information

10.3.2 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product

Overview

10.3.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product

Market Performance

10.3.4 AstraZeneca Business Overview

10.3.5 AstraZeneca SWOT Analysis

10.3.6 AstraZeneca Recent Developments

10.4 Arvinas

10.4.1 Arvinas Basic Information

10.4.2 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

10.4.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

10.4.4 Arvinas Business Overview

10.4.5 Arvinas Recent Developments

10.5 GSK

10.5.1 GSK Basic Information

10.5.2 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

10.5.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

10.5.4 GSK Business Overview

10.5.5 GSK Recent Developments

10.6 Bayer Corporation

10.6.1 Bayer Corporation Basic Information

10.6.2 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product

Overview

10.6.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product

Market Performance

10.6.4 Bayer Corporation Business Overview

10.6.5 Bayer Corporation Recent Developments

10.7 Pumis Biotechnology (BioNTech)

10.7.1 Pumis Biotechnology (BioNTech) Basic Information

10.7.2 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

10.7.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance

10.7.4 Pumis Biotechnology (BioNTech) Business Overview

10.7.5 Pumis Biotechnology (BioNTech) Recent Developments

10.8 Telix

10.8.1 Telix Basic Information

10.8.2 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

10.8.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

10.8.4 Telix Business Overview

10.8.5 Telix Recent Developments

10.9 Merus

10.9.1 Merus Basic Information

10.9.2 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

10.9.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

10.9.4 Merus Business Overview

10.9.5 Merus Recent Developments

10.10 Bicara Therapeutics

10.10.1 Bicara Therapeutics Basic Information

10.10.2 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Overview

10.10.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Market Performance

10.10.4 Bicara Therapeutics Business Overview

10.10.5 Bicara Therapeutics Recent Developments

10.11 Immatics

10.11.1 Immatics Basic Information

10.11.2 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product

Overview

- 10.11.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
- 10.11.4 Immatics Business Overview
- 10.11.5 Immatics Recent Developments
- 10.12 Fabhalta
 - 10.12.1 Fabhalta Basic Information
 - 10.12.2 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.12.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.12.4 Fabhalta Business Overview
 - 10.12.5 Fabhalta Recent Developments
- 10.13 Lytgobi
 - 10.13.1 Lytgobi Basic Information
 - 10.13.2 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.13.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.13.4 Lytgobi Business Overview
 - 10.13.5 Lytgobi Recent Developments
- 10.14 Talvey
 - 10.14.1 Talvey Basic Information
 - 10.14.2 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.14.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.14.4 Talvey Business Overview
 - 10.14.5 Talvey Recent Developments
- 10.15 Regeneron Pharmaceuticals
 - 10.15.1 Regeneron Pharmaceuticals Basic Information
 - 10.15.2 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.15.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.15.4 Regeneron Pharmaceuticals Business Overview
 - 10.15.5 Regeneron Pharmaceuticals Recent Developments
- 10.16 Ogsiveo
 - 10.16.1 Ogsiveo Basic Information
 - 10.16.2 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.16.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

- 10.16.4 Ogsiveo Business Overview
- 10.16.5 Ogsiveo Recent Developments

10.17 Skyclary

- 10.17.1 Skyclary Basic Information
- 10.17.2 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product

Overview

- 10.17.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

- 10.17.4 Skyclary Business Overview
- 10.17.5 Skyclary Recent Developments

10.18 Truqap

- 10.18.1 Truqap Basic Information
- 10.18.2 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
- 10.18.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

- 10.18.4 Truqap Business Overview
- 10.18.5 Truqap Recent Developments

10.19 Litfulo

- 10.19.1 Litfulo Basic Information
- 10.19.2 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
- 10.19.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market

Performance

- 10.19.4 Litfulo Business Overview
- 10.19.5 Litfulo Recent Developments

10.20 Vertex Pharmaceuticals

- 10.20.1 Vertex Pharmaceuticals Basic Information
- 10.20.2 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Overview

- 10.20.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Market Performance

- 10.20.4 Vertex Pharmaceuticals Business Overview
- 10.20.5 Vertex Pharmaceuticals Recent Developments

10.21 Jiangsu Hengrui Medicine

- 10.21.1 Jiangsu Hengrui Medicine Basic Information
- 10.21.2 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Overview

- 10.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Market Performance

- 10.21.4 Jiangsu Hengrui Medicine Business Overview
- 10.21.5 Jiangsu Hengrui Medicine Recent Developments
- 10.22 Akeso, Inc
 - 10.22.1 Akeso, Inc Basic Information
 - 10.22.2 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.22.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.22.4 Akeso, Inc Business Overview
 - 10.22.5 Akeso, Inc Recent Developments
- 10.23 Dizal Pharma
 - 10.23.1 Dizal Pharma Basic Information
 - 10.23.2 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.23.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.23.4 Dizal Pharma Business Overview
 - 10.23.5 Dizal Pharma Recent Developments
- 10.24 Shenzhen Yipusheng
 - 10.24.1 Shenzhen Yipusheng Basic Information
 - 10.24.2 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.24.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.24.4 Shenzhen Yipusheng Business Overview
 - 10.24.5 Shenzhen Yipusheng Recent Developments
- 10.25 Foreseen Biotechnology
 - 10.25.1 Foreseen Biotechnology Basic Information
 - 10.25.2 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.25.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
 - 10.25.4 Foreseen Biotechnology Business Overview
 - 10.25.5 Foreseen Biotechnology Recent Developments
- 10.26 Shanghai Henlius Biotech, Inc.
 - 10.26.1 Shanghai Henlius Biotech, Inc. Basic Information
 - 10.26.2 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
 - 10.26.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate

(ADC) Product Market Performance

10.26.4 Shanghai Henlius Biotech, Inc. Business Overview

10.26.5 Shanghai Henlius Biotech, Inc. Recent Developments

10.27 Suzhou Yilian Biopharmaceutical

10.27.1 Suzhou Yilian Biopharmaceutical Basic Information

10.27.2 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate

(ADC) Product Overview

10.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate

(ADC) Product Market Performance

10.27.4 Suzhou Yilian Biopharmaceutical Business Overview

10.27.5 Suzhou Yilian Biopharmaceutical Recent Developments

10.28 Beijing Hotgen Biotech

10.28.1 Beijing Hotgen Biotech Basic Information

10.28.2 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Overview

10.28.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC)

Product Market Performance

10.28.4 Beijing Hotgen Biotech Business Overview

10.28.5 Beijing Hotgen Biotech Recent Developments

10.29 Lixin Pharmaceutical Technology

10.29.1 Lixin Pharmaceutical Technology Basic Information

10.29.2 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate

(ADC) Product Overview

10.29.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate

(ADC) Product Market Performance

10.29.4 Lixin Pharmaceutical Technology Business Overview

10.29.5 Lixin Pharmaceutical Technology Recent Developments

10.30 Suzhou Zejing Biopharmaceutical

10.30.1 Suzhou Zejing Biopharmaceutical Basic Information

10.30.2 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug

Conjugate (ADC) Product Overview

10.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug

Conjugate (ADC) Product Market Performance

10.30.4 Suzhou Zejing Biopharmaceutical Business Overview

10.30.5 Suzhou Zejing Biopharmaceutical Recent Developments

11 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET FORECAST BY REGION

11.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast

11.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country

11.2.3 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region

11.2.4 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Type (2026-2035)

12.1.1 Global Forecasted Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2026-2035)

12.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Type (2026-2035)

12.1.3 Global Forecasted Price of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2026-2035)

12.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Application (2026-2035)

12.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) Forecast by Application

12.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (M USD)
- Table 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application
- Table 5. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Comparison by Region (M USD)
- Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Manufacturers (2020-2025)
- Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (M USD) by Manufacturers (2020-2025)
- Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers (2020-2025)
- Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in First in Class (FIC) Antibody Drug Conjugate (ADC) as of 2025)
- Table 11. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/KG) of Key Manufacturers (2020-2025)
- Table 12. Manufacturers? Manufacturing Sites, Areas Served
- Table 13. Manufacturers? Product Type
- Table 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 15. Mergers & Acquisitions, Expansion Plans
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Challenges
- Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
- Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
- Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
- Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading

Countries

Table 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (K MT)

Table 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (M USD)

Table 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Type (2020-2025)

Table 29. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2020-2025)

Table 30. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) by Type (2020-2025)

Table 31. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type (2020-2025)

Table 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price (USD/KG) by Type (2020-2025)

Table 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Application

Table 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application

Table 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2020-2025) & (K MT)

Table 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2020-2025)

Table 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application (2020-2025) & (M USD)

Table 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application (2020-2025)

Table 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)

Table 40. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)

Table 41. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2020-2025)

Table 42. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)

Table 43. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025)

Table 44. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)

Table 45. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)

Table 46. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)

Table 47. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)

Table 48. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)

Table 49. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)

Table 50. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)

Table 51. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)

Table 52. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)

Table 53. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)

Table 54. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) by Region(2020-2025)

Table 55. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (US\$ Million) by Region (2020-2025)

Table 56. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2020-2025)

Table 57. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 60. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 61. China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 62. Pfizer Basic Information

Table 63. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 64. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 65. Pfizer Business Overview

Table 66. Pfizer SWOT Analysis

Table 67. Pfizer Recent Developments

Table 68. Johnson and Johnson Basic Information

Table 69. Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 70. Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 71. Johnson and Johnson Business Overview

Table 72. Johnson and Johnson SWOT Analysis

Table 73. Johnson and Johnson Recent Developments

Table 74. AstraZeneca Basic Information

Table 75. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 76. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 77. AstraZeneca Business Overview

Table 78. AstraZeneca SWOT Analysis

Table 79. AstraZeneca Recent Developments

Table 80. Arvinas Basic Information

Table 81. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 82. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 83. Arvinas Business Overview

Table 84. Arvinas Recent Developments

Table 85. GSK Basic Information

Table 86. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 87. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 88. GSK Business Overview

Table 89. GSK Recent Developments

Table 90. Bayer Corporation Basic Information

Table 91. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 92. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 93. Bayer Corporation Business Overview

Table 94. Bayer Corporation Recent Developments

Table 95. Pumis Biotechnology (BioNTech) Basic Information

Table 96. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 97. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 98. Pumis Biotechnology (BioNTech) Business Overview

Table 99. Pumis Biotechnology (BioNTech) Recent Developments

Table 100. Telix Basic Information

Table 101. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 102. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 103. Telix Business Overview

Table 104. Telix Recent Developments

Table 105. Merus Basic Information

Table 106. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 107. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 108. Merus Business Overview

Table 109. Merus Recent Developments

Table 110. Bicara Therapeutics Basic Information

Table 111. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 112. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 113. Bicara Therapeutics Business Overview

Table 114. Bicara Therapeutics Recent Developments

Table 115. Immatix Basic Information

Table 116. Immatix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 117. Immatix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 118. Immatix Business Overview

Table 119. Immatix Recent Developments

Table 120. Fabhalta Basic Information

Table 121. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 122. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT),

Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 123. Fabhalta Business Overview

Table 124. Fabhalta Recent Developments

Table 125. Lytgobi Basic Information

Table 126. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 127. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 128. Lytgobi Business Overview

Table 129. Lytgobi Recent Developments

Table 130. Talvey Basic Information

Table 131. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 132. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 133. Talvey Business Overview

Table 134. Talvey Recent Developments

Table 135. Regeneron Pharmaceuticals Basic Information

Table 136. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 137. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 138. Regeneron Pharmaceuticals Business Overview

Table 139. Regeneron Pharmaceuticals Recent Developments

Table 140. Ogsiveo Basic Information

Table 141. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 142. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 143. Ogsiveo Business Overview

Table 144. Ogsiveo Recent Developments

Table 145. Skyclary Basic Information

Table 146. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 147. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 148. Skyclary Business Overview

Table 149. Skyclary Recent Developments

Table 150. Truqap Basic Information

Table 151. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 152. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 153. Truqap Business Overview

Table 154. Truqap Recent Developments

Table 155. Litfulo Basic Information

Table 156. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 157. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 158. Litfulo Business Overview

Table 159. Litfulo Recent Developments

Table 160. Vertex Pharmaceuticals Basic Information

Table 161. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 162. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 163. Vertex Pharmaceuticals Business Overview

Table 164. Vertex Pharmaceuticals Recent Developments

Table 165. Jiangsu Hengrui Medicine Basic Information

Table 166. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 167. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 168. Jiangsu Hengrui Medicine Business Overview

Table 169. Jiangsu Hengrui Medicine Recent Developments

Table 170. Akeso, Inc Basic Information

Table 171. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 172. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 173. Akeso, Inc Business Overview

Table 174. Akeso, Inc Recent Developments

Table 175. Dizal Pharma Basic Information

Table 176. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 177. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K

MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 178. Dizal Pharma Business Overview

Table 179. Dizal Pharma Recent Developments

Table 180. Shenzhen Yipusheng Basic Information

Table 181. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 182. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 183. Shenzhen Yipusheng Business Overview

Table 184. Shenzhen Yipusheng Recent Developments

Table 185. Foreseen Biotechnology Basic Information

Table 186. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 187. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 188. Foreseen Biotechnology Business Overview

Table 189. Foreseen Biotechnology Recent Developments

Table 190. Shanghai Henlius Biotech, Inc. Basic Information

Table 191. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 192. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 193. Shanghai Henlius Biotech, Inc. Business Overview

Table 194. Shanghai Henlius Biotech, Inc. Recent Developments

Table 195. Suzhou Yilian Biopharmaceutical Basic Information

Table 196. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 197. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 198. Suzhou Yilian Biopharmaceutical Business Overview

Table 199. Suzhou Yilian Biopharmaceutical Recent Developments

Table 200. Beijing Hotgen Biotech Basic Information

Table 201. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview

Table 202. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 203. Beijing Hotgen Biotech Business Overview

- Table 204. Beijing Hotgen Biotech Recent Developments
- Table 205. Lixin Pharmaceutical Technology Basic Information
- Table 206. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
- Table 207. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 208. Lixin Pharmaceutical Technology Business Overview
- Table 209. Lixin Pharmaceutical Technology Recent Developments
- Table 210. Suzhou Zejing Biopharmaceutical Basic Information
- Table 211. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
- Table 212. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 213. Suzhou Zejing Biopharmaceutical Business Overview
- Table 214. Suzhou Zejing Biopharmaceutical Recent Developments
- Table 215. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Region (2026-2035) & (K MT)
- Table 216. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region (2026-2035) & (M USD)
- Table 217. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
- Table 218. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
- Table 219. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
- Table 220. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
- Table 221. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Region (2026-2035) & (K MT)
- Table 222. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region (2026-2035) & (M USD)
- Table 223. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
- Table 224. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
- Table 225. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (Units)

Table 226. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)

Table 227. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Type (2026-2035) & (K MT)

Table 228. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Type (2026-2035) & (M USD)

Table 229. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price Forecast by Type (2026-2035) & (USD/KG)

Table 230. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) Forecast by Application (2026-2035)

Table 231. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of First in Class (FIC) Antibody Drug Conjugate (ADC)

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD), 2025-2035

Figure 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) (2020-2035)

Figure 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) & (2020-2035)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (M USD)

Figure 11. Company Assessment Quadrant

Figure 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Product Life Cycle

Figure 13. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Share by Manufacturers in 2025

Figure 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers in 2025

Figure 15. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025

Figure 16. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/KG) of Key Manufacturers in 2025

Figure 17. The Global 5 and 10 Largest Players: Market Share by First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue in 2025

Figure 18. Industry Chain Map of First in Class (FIC) Antibody Drug Conjugate (ADC)

Figure 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market PEST Analysis

Figure 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Porter's Five Forces Analysis

Figure 21. Global Merchandise Trade as a Percentage Of GDP

Figure 22. US - Imports of Goods by Country

Figure 23. China Exports by Country

- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type
- Figure 27. Sales Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2020-2025)
- Figure 28. Sales Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type in 2025
- Figure 29. Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2020-2025)
- Figure 30. Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type in 2025
- Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application
- Figure 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2020-2025)
- Figure 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application in 2025
- Figure 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application (2020-2025)
- Figure 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application in 2025
- Figure 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
- Figure 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2020-2025)
- Figure 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025)
- Figure 40. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
- Figure 41. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
- Figure 42. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
- Figure 43. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 44. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024

Figure 45. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) and Growth Rate (2020-2025)

Figure 49. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024

Figure 53. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024

Figure 55. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and

Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)

Figure 66. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region in 2024

Figure 67. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region in 2024

Figure 68. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 73. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)

Figure 79. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024

Figure 80. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (M USD)

Figure 81. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024

Figure 82. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region in 2024

Figure 90. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region in 2024

Figure 92. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 93. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 95. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production Market Share by Region (2020-2025)

Figure 103. North America First in Class (FIC) Antibody Drug Conjugate (ADC)

Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)

Figure 106. China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)

Figure 107. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Volume (2020-2035) & (K MT)

Figure 108. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Value (2020-2035) & (M USD)

Figure 109. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Type (2026-2035)

Figure 110. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Type (2026-2035)

Figure 111. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Application (2026-2035)

Figure 112. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Application (2026-2035)

I would like to order

Product name: Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Research Report 2026(Status and Outlook)

Product link: <https://marketpublishers.com/r/G18843671D69EN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G18843671D69EN.html>